Presently, DNase I (deoxyribonuclease I) has shown remarkable results in targeting NETS and extracellular DNA ex vivo lysis, thus demonstrating prothrombolytic potential when coupled with current thrombolytics.5,33,34 Recombinant human DNase I, under the name of dornase alfa, is currently labeled as a treatment in cystic fibrosis; dornase alfa hydrolyzes DNA present in the secretions of the airways in patients with cystic fibrosis, reducing viscosity, improving quality of life, and reducing mortality by infection.33,35. Here, DNASE1 is linked to cystic fibrosis.